LAPTM4B*2 allele is associated with the development of papillary thyroid carcinoma in Chinese women

Meng,Yue; Zhou,Rouli; Xu,Jianjun; Zhang,Qingyun

doi:10.3892/ol.2017.6503

LAPTM4B*2 allele is associated with the development of papillary thyroid carcinoma in Chinese women

Authors:
- Yue Meng
- Rouli Zhou
- Jianjun Xu
- Qingyun Zhang
View Affiliations

Affiliations: Department of Clinical Laboratory, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China, Department of Cell Biology, School of Basic Medical Sciences, Peking University, Beijing 100083, P.R. China
Published online on: June 30, 2017 https://doi.org/10.3892/ol.2017.6503
Pages: 3421-3428
Copyright: © Meng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lysosome‑associated protein transmembrane 4‑β (LAPTM4B) contains a polymorphic region that contributes to the increased risk of numerous types of tumor. However, no study has yet demonstrated an association between the expression of the LAPTM4B gene and tumor differentiation, and the reason that LAPTM4B polymorphisms affect the susceptibility of individuals to cancer remains to be elucidated. The present study assessed the possible association between LAPTM4B polymorphism and the risk of papillary thyroid carcinoma (PTC), and attempted to identify the underlying mechanism for variation in patient susceptibility with respect to transcription regulation in the polymorphism region. The case control study included 183 papillary thyroid carcinoma patients (132 females, 51 males) and 697 healthy controls (249 females, 448 males). Genomic DNA was extracted from the blood and the genotype of LAPTM4B was identified using polymerase chain reaction (PCR). The results of the PCR revealed that LAPTM4B allele *2 was associated with PTC risk in comparison with LAPTM4B allele *1 [odds ratio (OR), 1.968; 95% confidence interval (CI), 1.363‑2.841, P<0.001] in females, while LAPTM4B*2 was not associated with PTC risk in males (OR, 0.996, 95% CI, 0.615‑1.612, P=0.986). Notably, LAPTM4B polymorphism was not associated with clinical parameters in the female patient group. In addition, by performing a luciferase reporter assay in the PTC TPC1 and B‑CPAP cell lines, the transcriptional activity of the +10/+311 plasmid, representing LAPTM4B*2 was reduced compared with that of the +10/+292 plasmid representing LAPTM4B*1. In conclusion, the results of the present study suggested that LAPTM4B*2 was a susceptibility factor for PTC in the female Chinese population and this may not be caused by the transcriptional regulation of LAPTM4B polymorphism region in TPC1 and B‑CPAP cell lines.

View Figures

View References

1	Ito Y, Nikiforov YE, Schlumberger M and Vigneri R: Increasing incidence of thyroid cancer: controversies explored. Nat Rev Endocrinol. 9:178–184. 2013. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
3	Aschebrook-Kilfoy B, Grogan RH, Ward MH, Kaplan E and Devesa SS: Follicular thyroid cancer incidence patterns in the United States, 1980–2009. Thyroid. 23:1015–1021. 2013. View Article : Google Scholar : PubMed/NCBI
4	Davies L and Welch H: Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 140:317–322. 2014. View Article : Google Scholar : PubMed/NCBI
5	Vaccarella S, Dal Maso L, Laversanne M, Bray F, Plummer M and Franceschi S: The impact of diagnostic changes on the rise in thyroid cancer incidence: A population-based study in selected high-resource countries. Thyroid. 25:1127–1136. 2015. View Article : Google Scholar : PubMed/NCBI
6	Vergamini LB, Frazier AL, Abrantes FL, Ribeiro KB and Rodriguez-Galindo C: Increase in the incidence of differentiated thyroid carcinoma in children, adolescents and young adults: A population-based study. J Pediatr. 164:1481–1485. 2014. View Article : Google Scholar : PubMed/NCBI
7	Pellegriti G, Frasca F, Regalbuto C, Squatrito S and Vigneri R: Worldwide increasing incidence of thyroid cancer: Update on epidemiology and risk factors. J Cancer Epidemiol. 2013:9652122013. View Article : Google Scholar : PubMed/NCBI
8	Xu L, Port M, Landi S, Gemignani F, Cipollini M, Elisei R, Goudeva L, Müller JA, Nerlich K, Pellegrini G, et al: Obesity and the risk of papillary thyroid cancer: A pooled analysis of three case-control studies. Thyroid. 24:966–974. 2014. View Article : Google Scholar : PubMed/NCBI
9	Zou M, Baitei EY, Al-Rijjal RA, Parhar RS, Al-Mohanna FA, Kimura S, Pritchard C, Binessa HA, Alzahrani AS, Al-Khalaf HH, et al: TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer. Oncogene. 35:1909–1918. 2016. View Article : Google Scholar : PubMed/NCBI
10	Chen GG, Vlantis AC, Zeng Q and van Hasselt CA: Regulation of cell growth by estrogen signaling and potential targets in thyroid cancer. Curr Cancer Drug Targets. 8:367–377. 2008. View Article : Google Scholar : PubMed/NCBI
11	Yang H, Lin M, Xiong F, Yang Y, Nie X, McNutt MA and Zhou R: Combined lysosomal protein transmembrane 4 beta-35 and argininosuccinate synthetase expression predicts clinical outcome in hepatocellular carcinoma patients. Surg Today. 41:810–817. 2011. View Article : Google Scholar : PubMed/NCBI
12	Shao GZ, Zhou RL, Zhang QY, Zhang Y, Liu JJ, Rui JA, Wei X and Ye DX: Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene. 22:5060–5069. 2003. View Article : Google Scholar : PubMed/NCBI
13	Fan M, Liu Y, Zhou R and Zhang Q: Association of LAPTM4B gene polymorphism with breast cancer susceptibility. Cancer epidemiol. 36:364–368. 2012. View Article : Google Scholar : PubMed/NCBI
14	Liu Y, Zhang QY, Qian N and Zhou RL: Relationship between LAPTM4B gene polymorphism and susceptibility of gastric cancer. Ann Oncol. 18:311–316. 2007. View Article : Google Scholar : PubMed/NCBI
15	Deng LJ, Zhang QY, Liu B and Zhou RL: Relationship between LAPTM4B gene polymorphism and susceptibility of lung cancer. Beijing Da Xue Xue Bao. 37:302–305. 2005.(In Chinese). PubMed/NCBI
16	Cheng XJ, Xu W, Zhang QY and Zhou RL: Relationship between LAPTM4B gene polymorphism and susceptibility of colorectal and esophageal cancers. Ann Oncol. 19:527–532. 2008. View Article : Google Scholar : PubMed/NCBI
17	Meng F, Li H, Zhou R, Luo C, Hu Y and Lou G: LAPTM4B gene polymorphism and endometrial carcinoma risk and prognosis. Biomarkers. 18:136–143. 2013. View Article : Google Scholar : PubMed/NCBI
18	Meng F, Song H, Luo C, Yin M, Xu Y, Liu H, Zhou R and Lou G: Correlation of LAPTM4B polymorphisms with cervical carcinoma. Cancer. 117:2652–2658. 2011. View Article : Google Scholar : PubMed/NCBI
19	Yang H, Zhai G, Ji X, Xiong F, Su J and McNutt MA: Correlation of LAPTM4B polymorphisms with gallbladder carcinoma susceptibility in Chinese patients. Med Oncol. 29:2809–2813. 2012. View Article : Google Scholar : PubMed/NCBI
20	Xu Y, Liu Y, Zhou R, Meng F, Gao Y, Yang S, Li X, Yang M and Lou G: LAPTM4B polymorphisms is associated with ovarian cancer susceptibility and its prognosis. Jpn J Clin Oncol. 42:413–419. 2012. View Article : Google Scholar : PubMed/NCBI
21	Zhang M, Zhou R, Xu J and Zhang Q: Relationship between LAPTM4B gene polymorphism and susceptibility of malignant melanoma in Chinese patients. Transl Oncol. 7:638–643. 2014. View Article : Google Scholar : PubMed/NCBI
22	Wang B, Xu J, Zhou R and Zhang Q: Association of LAPTM4B gene polymorphism with nasopharyngeal carcinoma susceptibility in a Chinese population. Med Oncol. 30:4702013. View Article : Google Scholar : PubMed/NCBI
23	Cuccurullo V and Mansi L: AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual (7th edition). European Journal of Nuclear Medicine and Molecular Imaging. 38:408. 2011. View Article : Google Scholar
24	Zhang M, Xu JJ, Zhou RL and Zhang QY: cAMP responsive element binding protein-1 is a transcription factor of lysosomal-associated protein transmembrane-4 Beta in human breast cancer cells. PLoS one. 8:e575202013. View Article : Google Scholar : PubMed/NCBI
25	Aschebrook-Kilfoy B, Ward MH, Sabra MM and Devesa SS: Thyroid cancer incidence patterns in the United States by histologic type, 1992–2006. Thyroid. 21:125–134. 2011. View Article : Google Scholar : PubMed/NCBI
26	Chen AY, Jemal A and Ward EM: Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer. 115:3801–3807. 2009. View Article : Google Scholar : PubMed/NCBI
27	Zhao J, Huang X, Yang M, Li M and Zheng J: Association between the FTOrs8050136 polymorphism and cancer risk: A meta-analysis. Fam cancer. 15:145–153. 2016. View Article : Google Scholar : PubMed/NCBI
28	Lee YC, Chung JH, Kim SK, Rhee SY, Chon S, Oh SJ, Hong IK and Eun YG: Association between interleukin 17/interleukin 17 receptor gene polymorphisms and papillary thyroid cancer in Korean population. Cytokine. 71:283–288. 2015. View Article : Google Scholar : PubMed/NCBI
29	Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Máximo V, Botelho T, Seruca R and Sobrinho-Simões M: BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 22:4578–4580. 2003. View Article : Google Scholar : PubMed/NCBI
30	Horn-Ross PL, Canchola AJ, Ma H, Reynolds P and Bernstein L: Hormonal factors and the risk of papillary thyroid cancer in the California Teachers Study cohort. Cancer Epidemiol Biomarkers Prev. 20:1751–1759. 2011. View Article : Google Scholar : PubMed/NCBI
31	Milkereit R, Persaud A, Vanoaica L, Guetg A, Verrey F and Rotin D: LAPTM4b recruits the LAT1-4F2hc Leu transporter to lysosomes and promotes mTORC1 activation. Nat commun. 6:72502015. View Article : Google Scholar : PubMed/NCBI
32	Meng F, Chen X, Song H and Lou G: LAPTM4B down regulation inhibits the proliferation, invasion and angiogenesis of HeLa cells in vitro. Cell Physiol Biochem. 37:890–900. 2015. View Article : Google Scholar : PubMed/NCBI
33	Zhou L, He XD, Yu JC, Zhou RL, Yang H, Qu Q and Rui JA: Overexpression of LAPTM4B promotes growth of gallbladder carcinoma cells in vitro. Am J Surg. 199:515–521. 2010. View Article : Google Scholar : PubMed/NCBI
34	Zhou L, He XD, Yu JC, Zhou RL, Shan Y and Rui JA: Overexpression of LAPTM4B-35 attenuates epirubucin-induced apoptosis of gallbladder carcinoma GBC-SD cells. Surgery. 150:25–31. 2011. View Article : Google Scholar : PubMed/NCBI
35	Tan X, Thapa N, Sun Y and Anderson RA: A kinase-independent role for EGF receptor in autophagy initiation. Cell. 160:145–160. 2015. View Article : Google Scholar : PubMed/NCBI
36	Liu X, Xiong F, Wei X, Yang H and Zhou R: LAPTM4B-35, a novel tetratransmembrane protein and its PPRP motif play critical roles in proliferation and metastatic potential of hepatocellular carcinoma cells. Cancer sci. 100:2335–2340. 2009. View Article : Google Scholar : PubMed/NCBI